Ibrutinib, as a single agent, is helpful in managing CLL, unique subtypes of lymphoma and also other B-cell malignancies Unless of course unacceptable toxicity or disease progression is observed. As a consequence of chronic exposure of ibrutinib for the duration of cure, lymphoma cells could attain compensatory survival pathways, genetic https://leonardd332zsj4.p2blogs.com/profile